Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous disease that currently accounts for 15% of all liver cancers and approximately 3%…
Teresa Macarulla
Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
The Horizon 2020 funded NoCANTher European Consortium*, coordinated by IMDEA Nanociencia, rolls out the clinical phase of the project. The…
